t
Feedback plc announced that on 23 December 2025, CEO Tom Oakley purchased 60,904 ordinary shares at 8.19 pence per share. Concurrently, Emma Oswick (Stuart), Non-Board CFO, purchased 60,459 ordinary shares at 8.27 pence per share on the same date.
| Date | 23 Dec 2025 |
| Time | 15:33:08 |
| Category | Director/PDMR dealings |
| ID | 7148M |
Feedback Plc
Director/PDMR shareholding
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces that on 23 December 2025 the Company was notified of the following Director and PDMR dealing(s) in the Company's ordinary shares of 1 penny each ("Ordinary Shares"):
Tom Oakley, CEO, purchased 60,904 Ordinary Shares at a price of 8.19 pence per Ordinary Share.
Emma Oswick (Stuart), (Non-Board) CFO, purchased 60,459 Ordinary Shares at a price of 8.27 pence per Ordinary Share.
Details of the Ordinary Shares held are detailed in the table below:
|
Director/ PDMR |
Position |
Existing interest in Ordinary Shares |
Ordinary Shares purchased |
Total beneficial interest in Ordinary Shares |
Total interest in Company's issued share capital |
|
Tom Oakley |
CEO |
50,000 |
60,904 |
110,904 |
0.25% |
|
Emma Oswick (Stuart)
|
(Non-Board) CFO |
- |
60,459 |
60,459 |
0.14% |
The notification set out below is provided in accordance with the requirements of the UK Market Abuse Regulation:
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Names
|
a) Tom Oakley b) Emma Oswick (Stuart)
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
a) CEO b) (Non-Board) CFO |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Feedback plc |
|||
|
b)
|
LEI
|
213800UGOF2GT2U2RV90 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of 1 penny each in Feedback plc |
|||
|
|
|
||||
|
Identification code |
GB00BJN59X09 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares Purchase of Ordinary Shares |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
a) 8.19 |
a) 60,904 |
|
|
|
|
|
b) 8.27 |
b) 60,459 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
a) £4,988.04 b) £4,999.96 |
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
a) 23 December 2025 b) 23 December 2025 |
|||
|
f)
|
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
|||
--Ends--
Enquiries:
|
Feedback plc Tom Oakley, CEO Emma Oswick, CFO |
+44 (0) 20 3997 7634 |
|
|
|
|
Panmure Liberum Limited (NOMAD and Broker) Emma Earl/Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) |
+44 (0)20 7886 2500 |
|
|
|
|
Walbrook PR Ltd; |
Tel: 020 7933 8780 or [email protected] |
|
Nick Rome/Joe Walker |
07748 325 236 or 07407 020 470 |
About Feedback plc
Feedback plc liberates the data and knowledge from multiple healthcare IT systems and delivers better workflow to enable clinicians to communicate, collaborate and provide the best healthcare for their patients. We connect care settings with diagnostic and other relevant data to drive better, faster, safer decision that improve outcomes for patients.
By linking different clinical systems together into a seamless view of the patient, we can streamline patient pathways and deliver a digital health and diagnostics record across multiple care providers.
Bleepa® is our communication and collaboration platform that displays clinical results at a certified and regulated quality, which enables multi-disciplinary team working and diagnostic-enhanced advice and guidance. CareLocker® is our patient-facing platform that gives patients access and control over their diagnostic and other clinical data.
The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.